Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Torben Noerup Nielsen who wrote (5409)	1/11/2002 11:42:34 PM
From: Miljenko Zuanic	Respond to of 52153

It is always easy to blame government bureaucrats at FDA, while business play clean, fair, and without cheating. <<Corixa stated that although it has been preparing for a February panel review, the U.S. Food and Drug Administration (FDA) has advised the company that, as a result of the extensive amount of material submitted in response to the agency's complete review letter and subsequent discussions, ...>> Maybe FDA asked CRXA for reformulation of the response to review letter? Why simple can not be kept simple? Miljenko